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Abstract
Purpose In preterm infants, the biotransformation of mid-
azolam (M) to 1-OH-midazolam (OHM) by cytochrome
P450 3A4 (CYP3A4) is developmentally immature, but it is
currently unknown whether the glucuronidation of OHM to
1-OH-midazolam glucuronide (OHMG) is also decreased.
The aim of our study was to investigate the urinary
excretion of midazolam and its metabolites OHM and
OHMG in preterm neonates following the intravenous (IV)
or oral (PO) administration of a single M dose.
Methods Preterm infants (post-natal age 3–13 days, gesta-
tional age 26–34 4/7 weeks) scheduled to undergo a
stressful procedure received a 30-min IV infusion (n=15)
or a PO bolus dose (n=7) of 0.1 mg/kg midazolam. The
percentage of midazolam dose excreted in the urine as M,
OHM and OHMG up to 6 h post-dose was determined.
Results The median percentage of the midazolam dose
excreted as M, OHM and OHMG in the urine during the
6-h interval after the IV infusion was 0.44% (range 0.02–
1.39%), 0.04% (0.01–0.13%) and 1.57% (0.36–7.7%),
respectively. After administration of the PO bolus dose,
the median percentage of M, OHM and OHMG excreted in
the urine was 0.11% (0.02–0.59%), 0.02% (0.00–0.10%)
and 1.69% (0.58–7.31%), respectively. The proportion of
the IV midazolam dose excreted as OHMG increased
significantly with postconceptional age (r=0.73, p <0.05).
Conclusion The glucuronidation of OHM appears imma-
ture in preterm infants less than 2 weeks of age. The
observed increase in urinary excretion of OHMG with
postconceptional age likely reflects the combined matura-
tion of glucuronidation and renal function.
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Introduction
The plasma clearance rate of the benzodiazepine midazo-
lam (M) is widely used as an in vivo surrogate measure-
ment of cytochrome P450 3A4/5 (CYP3A4/5) activity
[1, 2]. We have previously demonstrated that midazolam
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clearance is substantially reduced in preterm infants as
compared to older children and adults due to the develop-
mental immaturity of CYP3A4 metabolism (i.e. low
CYP3A4 activity) [3]. In adults, the main hydroxylated
metabolite of midazolam, 1-OH-midazolam (OHM), is
glucuronidated to 1-OH-midazolam glucuronide (OHMG)
[4]. In vitro data suggest that UGT2B4, UGT2B7 and, to a
lesser extent, UGT1A4, are responsible for the glucuronida-
tion of OHM in humans [5]. Interestingly, it has also been
recently shown that midazolam can be directly glucuroni-
dated by UGT1A4, a pathway that becomes more important
quantitatively in determining midazolam plasma clearance in
individuals with low constitutive CYP3A4/5 activity [6, 7].
The UDP-glycosyltransferase genes mainly encode
UDP-glucuronosyltransferases (UGTs), a superfamily of
enzymes. Four families of genes have been identified
within this superfamily: UGT1, UGT2, UGT3 and UGT8.
The UGT1 and UGT2 gene families are critical in the
detoxification of endogenous and exogenous (e.g. drugs)
chemicals, and at least 16 genes have been identified to date
in humans [8].
As with CYP3A4, glucuronidation activity shows a
developmental surge after birth [9]. However, the exact
developmental profiles for the various UGT isoforms have
not been elucidated to date. In vitro data suggest that
UGT1A4, UGT2B4 and UGT2B7 have a low activity
profile immediately after birth that increases to adult levels
within the first 1–2 years of life, but the developmental
pattern seems to be unique for each individual enzyme [9–
12]. These data have been corroborated by in vivo
pharmacokinetic data for morphine [13] and zidovudine
[14], both of which are UGT2B7 substrates.
Based on the available data, we hypothesized that the
glucuronidation of midazolam and its main metabolite OHM
is significantly reduced in preterm infants as compared to
adults. While ethical and practical issues limit the number
and volume of blood samples that can be obtained to study
drug metabolism in preterm infants [15], urinary metabolite
profiles can provide an alternative method for examining
drug biotransformation [16]. Therefore, we have examined
the urinary excretion of midazolam, OHM and OHM
glucuronide in preterm neonates after a single midazolam
dose with the aim of further elucidating the developmental
pattern of 1-OH-midazolam glucuronidation.
Methods
The samples used for analysis in this current study were
obtained from subjects participating in a larger investiga-
tion designed to assess the plasma pharmacokinetics and
pharmacodynamics of midazolam in preterm neonates [3,
17, 18]. The quantification of midazolam and its metabo-
lites from urine specimens was not included in the original
studies consequent to resource limitations at the time of
sample collection.
Patients
Neonates were eligible for study entry (into the original
study) if they were scheduled to undergo a stressful
procedure (e.g. tracheal tube suction, elective nasopharyn-
geal intubation) and had a pre-existing indwelling arterial
catheter placed for purposes of medical care. Patients were
excluded if they were receiving morphine, dobutamine,
dopamine or a drug known to affect CYP3A activity. In
addition, patients were excluded from the study if they had
significant underlying hemodynamic, renal, hepatic or
neurologic dysfunction.
The infants were recruited from the Neonatal Intensive
Care Unit of the Erasmus MC–Sophia Children’s Hospital.
This research protocol was approved by the Human Ethical
Committee of the Erasmus MC in Rotterdam. Written,
informed consent was obtained from all parents or legal
guardians prior to the enrollment of subjects in the study.
Drug administration and sample collection
Midazolam (Dormicum injection; Roche Laboratories, The
Netherlands) was administered intravenously (IV) as a single
0.1 mg/kg dose in a 5% glucose solution (0.03 mg/ml),
infused by a syringe pump over a 30-min period through
microbore tubing into a peripheral vein or a central venous
catheter. Oral midazolam (PO) at a concentration of 0.5 mg/ml
was diluted with 5% glucose to a final volume of 0.5 ml and
given as a single 0.1 mg/kg dose through the gastric tube,
followed by 0.5 ml of 5% glucose 5% to ensure that no
midazolam remained in the tube.
Urine samples were collected in 2-h aliquots for up to
6 h post-dose. The collection method consisted of placing a
cotton gauze in the child’s diaper that was separated from
the diaper absorbing material by a small plastic sheet.
Diapers (including gauze and sheet) were weighed before
and after each 2-h period to determine urine output. Urine
was pressed from the gauze into a collection tube.
Incidental fecal material was removed from the diaper as
much as possible before weighing. For each urine collec-
tion interval, the sample was mixed by repeated inversion,
the volume determined and an aliquot (2–5 ml) poured into
a screw-capped, polypropylene storage vial which was
immediately placed at −80°C until analysis.
As described previously [3], serial blood samples (n=8 at
pre-dose and 0.5, 1, 2, 4, 6, 12 and 24 h post-dose) were
obtained from an indwelling cannula (placed for clinical
management needs not related to the study) after the
midazolam dose had been administered.
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Analytical methods
Urine and plasma samples were analyzed for midazolam
and OHM by gas chromatography with mass spectrometric
detection (Hewlett Packard 6890; Agilent Technologies,
Palo Alto, CA) [3]. The urine samples were analyzed before
and after β- glucuronidase incubation, as described earlier
[19]. The column used was a J&W Scientific DB-17 EVDX
(0.2 μm × 25 m; J&W Scientific, Folsom, CA). Diazepam
(Elkins Sinn, Cherry Hill, NJ), 5 µl of a 500 ng/ml solution,
was added to each sample as an internal standard, and solid
phase extraction was performed using a Varian Bond Elut
column (Varian, Palo Alto, CA). The range of linearity for the
analytical method was from 1 to 500 ng/ml for midazolam,
and from 0.5 to 500 ng/ml for OHM. The inter-day coefficient
of variation (CV) was consistently less than 10% for both
midazolam and OHM at concentrations spanning the range of
linearity. The intra-day CVs were also less than 10% for both
midazolam and OHM at concentrations spanning the range of
linearity. The lower limit of quantitation was 1 ng/ml for
midazolam and 0.5 ng/ml for OHM using 0.2-ml sample
volumes. Frozen stability (i.e. ≥90% of original concentra-
tion) was documented for midazolam and OHM in urine for a
period of 8 years. All samples were analyzed in duplicate, and
the resultant mean concentration was used in the pharmaco-
kinetic and statistical analyses.
Pharmacokinetic analysis
The OHM glucuronide concentration was calculated by
subtracting the total OHM concentration from the OHM
concentration after de-glucuronidation, which was next
corrected for molecular weight (MW; 517.9 and 341.8
for OHMG and OHM, respectively) using the equation
OHMG = OHM × (517.9/341.8). Amounts of midazolam
and metabolites excreted in the urine were calculated by
multiplying the concentration with urine volume per post-
dose interval. The proportion of dose excreted was
calculated by dividing the amount excreted in the urine
over all post-dose intervals by the midazolam dose
administered, with a correction for molecular weight where
applicable (midazolam MW 325.8).
Plasma pharmacokinetic parameters were calculated
using non-compartmental pharmacokinetic analysis as
described previously [3].
Statistical analysis
The results are expressed as mean ± standard deviation (SD)
unless stated otherwise. Non-normally distributed data were
expressed as median values (range). The association of
continuous values (i.e. postnatal age, postconceptional age)
and calculated pharmacokinetic parameters are given as the
Spearman’s (rs) correlation coefficient. All statistical analy-
ses were performed using SPSS software (ver. 13.0; SPSS,
Chicago, IL) and assumed a significance limit of α=0.05.
Results
Demographics and data collection
Urine samples suitable for analysis (e.g. complete collec-
tions of at least 2 ml per interval) were available from 15
and seven neonates receiving IV and PO midazolam,
respectively. Demographic data and clinical characteristics
of this study cohort are summarized in Table 1. In one patient
after IV dosing, urine could not be collected from 2–4 h and
4–6 h post-doseinterval due to gross fecal contamination of
the specimen. Consequently, data from this patient were
excluded from the analyses. In two patients receiving IV
midazolam, the diaper could not be changed at the 4 h time
point for clinical reasons. Hence, from these patients, urine
was collected as a 4 h aliquot during the 2–6 h post-dose
interval.
Urinary excretion of midazolam and metabolites
The recovery of midazolam and of its metabolites OHM and
OHMG showed large inter-individual variation. The total
amounts of midazolam, OHM and OHMG [median (range)]
recovered in urine up to 6 h post-IV dose were 396 (21–2080)
ng, 5 (11–200) ng and 2253 (561–14681) ng, respectively.
Following the PO midazolam dosing, midazolam, OHM and
Patient characteristics IV midazolam PO midazolam
Total (male/female) (n) 15 (9/6) 7 (6/1)
Gestational age (weeks) 27 6/7 (26 2/7–34 4/7) 27 (26–27 6/7)
Postnatal age (days) 7 (3–11) 6 (5–13)
Birth weight (grams) 1040 (745–1365) 920 (745–1190)
Study weight (grams) 980 (900–1535) 910 (825–1165)
Ventilation (none/NPT/ETT) 1/6/8 0/3/4
Table 1 Patient characteristics
NPT, Nasopharyngeal tube;
ETT, endotracheal tube; IV,
intravenous; PO, oral dose
Values are expressed as median,
with the range in parenthesis,
unless indicated otherwise
Eur J Clin Pharmacol (2010) 66:165–170 167
OHMG were recovered in the urine in amounts of 128 (22–
562), 21 (2–101) and 2906 (754–9988) ng, respectively.
The percentages of the IV midazolam dose excreted as
midazolam, OHM and OHMG in the urine over a 6-h post-
dose interval were 0.44% (0.02–1.39%), 0.04% (0.01–0.13%)
and 1.57% (0.36–7.7%), respectively. After PO midazolam
dosing, the percentage of midazolam, OHM and OHMG was
0.11% (0.02–0.59%), 0.02% (0.00–0.10%) and 1.69% (0.58–
7.31%), respectively. The percentage of each of the these
analytes recovered in the urine was not significantly different
after IVor PO midazolam administration.
Midazolam urinary excretion as a surrogate marker for drug
metabolism
We found a stronger positive correlation between the
proportion of the IV midazolam dose excreted as OHMG
and postconceptional age (r=0.73, p=0.004) than between
the same proportion and postnatal age (r =0.47, p=0.09),
Fig. 1. Similarly, we found a positive correlation between
the proportion of PO midazolam excreted as total OHM
(glucuronidated and not glucuronidated) and postconcep-
tional age (r=0.74 p=0.003) but not postnatal age (0.5,
0.06). In contrast, no correlation was apparent between the
proportion of midazolam excreted as OHM or midazolam
and age. We did not find a postconceptional age-related
change in the M/total OHM urinary ratio (as possible
marker of CYP3A activity) after IV midazolam adminis-
tration (r=0.303, p=0.29). We also did not find a
correlation between for bodyweight-corrected midazolam
plasma clearance after IV midazolam (also as a surrogate
marker of CYP3A activity) and M/total OHM urinary ratio
r=−0.165, p=0.590). The addition of the data of seven
patients who received the oral midazolam dose (Fig. 1) to
the aforementioned analyses of the IV data did not
appreciably change the results with respect to significant
associations.
Discussion
Despite its extensive clinical use in the treatment of neonates
and young infants [20], limited data exist which profile the
biotransformation and renal excretion of midazolam and its
metabolites. The data from this study provide additional
insight and understanding of the developmental changes in
midazolam disposition in preterm infants.
In the study reported here, the median (range) percentage
of midazolam and total OHM (OHM+OHMG) recovered in
the urine of preterm infants over a 6-h period following the
IV administration of a single midazolam dose was 0.44%
(range 0.02–1.39%) and 1.64% (0.37–7.9%), respectively.
This is in contrast to data reported in adults where the
median (range) percentage of the midazolam dose recov-
ered in urine up to 6 h following the administration of a
single IV dose was 0.14% (0.02–0.40%) for midazolam and
30.7% (1.3–52.6%) for total OHM [21]. As preterm infants
have significantly lower midazolam clearance rates than
adults [3, 4], the low percentage of midazolam recovered as
metabolites in our preterm infants is not unexpected.
Considering an average plasma midazolam elimination
half-life of 1–2 h in adults [4], one would predict that
>90% of a dose would be cleared from the plasma over a 6-
h post-dose time period. In contrast, the midazolam
elimination half life in preterm infants (6–8 h) is signifi-
cantly longer than that in adults. Hence, during a 6-h post-
dose interval in preterm infants, it is possible that only 50%
or less of the total midazolam dose would be cleared from
the plasma. This caveat must be considered when our data
from preterm infants are compared with those previously
reported for adults, [21] especially when using total OHMG
excretion as a potential surrogate for the activity of UGT
isoforms capable of producing the OHMG metabolite.
In contrast, the percentage of midazolam recovered in
the urine as the parent drug appears to be higher in our
preterm infants than in adults [0.44% (0.01–1.39%) vs.
0.14% (0.02±0.40%), respectively]. This observation may
be explained by the higher proportion of urinary midazolam
excretion in the presence of developmentally immature
CYP3A4/5 activity as an active CYP3A4/5 enzyme which
would be expected to markedly reduce midazolam clear-
ance due to drug biotransformation. An analogous situation
occurs with caffeine in the neonate where >50% of its total
clearance in the first few days and weeks of postnatal life
results from renal excretion of the unchanged drug, an
amount which diminishes over time as the activity of
enzymes capable of metabolizing caffeine mature [23, 24].
We have previously shown in the same patient popula-
tion that the median OHM AUC0–t/M AUC0–t ratio in
plasma was low (0.09) with large inter-individual variation
(range <0.001–1, CV 191%) when compared to that of
older children (2 days to 17 years of age; OHM/M ratio
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168 Eur J Clin Pharmacol (2010) 66:165–170
0.14±0.21) [3, 19]. We speculated that the low OHM/M
ratio in the preterm infants was due to developmentally
immature CYP3A4/5 activity. However, based on the data
reported here, with low (unconjugated) OHM and OHMG
urinary excretion, we contend that the low OHM/M plasma
ratio observed in preterm infants is more likely to be
compounded by immature CYP3A4/5 activity and relative-
ly less immature UGT activity. Unfortunately, due to ethical
restraints on blood sample volumes, we were not able to
also measure OHMG in plasma, which could have further
supported this hypothesis.
We observed a postconceptional age-related increase in
urinary excretion of OHMG and total OHM (OHM+OHMG),
but not of midazolam or OHM in our patients. This
observation also suggests, that independent of a likely
increase in OHM formation with age consequent to CYP3A
maturation, glucuronidation capacity seems to bemoremature
than that of CYP3A.
These data should be interpreted with care, however, as in
addition to immature drug metabolism, immature renal
function in our preterm patient cohort may also have
contributed to a lower urinary recovery of midazolam as
OHM and OHMG compared to adults [22]. Urinary
metabolite ratios may be dependent on renal function,
especially in those instances when the contribution of renal
clearance of the parent drug is low in relation to its metabolic
clearance [16, 25]. Unfortunately, GFR was not routinely
measured in our patients. Due to the relationship between
GFR and postconceptional age in preterm infants, in light of
the small sample size studies, we were also not able to
correct our findings for estimated GFR. However, limited
data from a small group of asphyxiated term newborns
appear to support our findings in relation to the overall
importance of renal function as a determinant of midazolam
clearance [26].
Interestingly, recent in vitro data have shown that, in
addition to the glucuronidation of the hydroxylated metab-
olites of midazolam, the parent drug can be metabolized by
UGT1A4 to a midazolam N-glucuronide (MG) [6]. In
adults, this particular metabolite accounts for only a minor
fraction of the midazolam metabolites formed. In the
presence of a CYP3A4/5 inhibitor, midazolam is largely
biotransformed to midazolam N-glucuronide at the expense
of OHM(G) formation [6]. However, given in vitro data
which demonstrate that UGT1A4 activity is reduced during
early life, [11], it is likely that developmentally associated
reductions in both CYP3A4/5 and UGT activity contribute to
overall reductions in midazolam biotransformation in neo-
nates, resulting in renal clearance playing a greater role—
proportionally—in drug excretion.
Although we did not find a significant difference in
urinary midazolam and metabolite excretion after IV and
PO excretion, visual inspection of the data suggest that less
midazolam and more OHMG is excreted after oral than
after IV administration. This observation could be contrib-
uted to first-pass metabolism of orally administered mid-
azolam in the intestine and liver. Possibly, due to the
immaturity of intestinal CYP3A, as we showed earlier in
our midazolam pharmacokinetic studies, this difference did
not reach statistical significance[17]. These results should
be interpreted in the context of the small sample size and
the large inter-individual variation observed.
As noted above, our study has several limitations that
deserve consideration. First, truncation of urine collection
to a 6-h post-dose period was necessitated largely by the
fact that subjects did not have indwelling urinary catheters
and that the application of adhesive-containing external
urine collection bags is associated with excoriation risk in
neonates. We also observed that the odds of significant
fecal contamination of the gauze used for passive urine
collection increased as the collection period was extended.
Second, as shown for the CYP2D6 probe dextromethor-
phan, urinary pH can seriously affect metabolite ratios and,
hence, reduce their usefulness as a metabolic probe [27].
Unfortunately, due to our urinary collection method, we
were not able to measure urinary pH directly after the
neonate had urinated. Urine was collected over a 2-h period
in a gauze, during which time the urinary pH may have
significantly changed. Also, the extent to which the
midazolam urinary ratio is affected by urinary pH has not,
to our knowledge, been studied. Finally, our data did not
enable true elucidation of the isoform specificity nor did
they permit assessment of the potential contribution of renal
glucuronidation (by UGT2B4 and UGT2B7) [28, 29] to the
overall extent of midazolam biotransformation.
In conclusion, our experimental data corroborate previous
reports of developmental immaturity in the activity of
enzymes known to be responsible for midazolam biotransfor-
mation. In sick preterm infants in whom the activity of drug
metabolizing enzymes is known to be low, the expected
postnatal maturation in renal function provides a quantitative-
ly important route for the clearance of midazolam and its
metabolites, with renal clearance predominating during the
first few weeks of life. Our data also illustrate the importance
of considering the impact of ontogeny on both drug
metabolism and renal clearance when examining apparent
age-associated differences in drug disposition in the neonatal
period.
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